Immunotherapy in Lung Cancer: Are the Promises of Long-Term Benefit Finally Met?
CTLA-4
Immune checkpoint inhibitors
Immunotherapy
NSCLC
PD-1
PD-L1
SCLC
TMB
bTMB
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
1
1
2022
pubmed:
2
1
2022
medline:
5
1
2022
Statut:
ppublish
Résumé
Over the last few years, agents targeting immune checkpoints have shown potential to improve therapeutic outcomes in patients with lung cancer in multiple clinical settings. Inhibitors of PD-1/PD-L1 have been approved for the treatment of different types of lung cancer by the FDA either alone or in combination with chemotherapy or other immune checkpoint inhibitors, such as anti-CTLA-4 agents. The introduction of these agents in clinical practice has revolutionized the therapeutic approach to lung cancer, keeping the promises of long-term benefit in selected patient populations. The therapeutic indications of immunotherapy in lung cancer are rapidly growing, and multiple combinations entered clinical practice or are under active development. Furthermore, the quest for a reliable predictive biomarker is still ongoing to overcome the limits of currently approved tests for patients' selection. In this review, we summarized the current status and progress of anti-PD-1/PD-L1 agents in lung cancer treatment.
Identifiants
pubmed: 34972964
doi: 10.1007/978-3-030-79308-1_4
doi:
Substances chimiques
B7-H1 Antigen
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-142Informations de copyright
© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021). Cancer statistics, 2021. CA: a Cancer Journal for Clinicians, 71(1), 7–33. https://doi.org/10.3322/caac.21654
doi: 10.3322/caac.21654
Thomas, A., & Giaccone, G. (2015). Why has active immunotherapy not worked in lung cancer? Annals of Oncology, 26(11), 2213–2220. https://doi.org/10.1093/annonc/mdv323
doi: 10.1093/annonc/mdv323
pubmed: 26232492
pmcid: 4621028
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer, 12(4), 252–264. https://doi.org/10.1038/nrc3239
doi: 10.1038/nrc3239
pubmed: 22437870
pmcid: 4856023
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery, 8(9), 1069–1086. https://doi.org/10.1158/2159-8290.CD-18-0367
doi: 10.1158/2159-8290.CD-18-0367
pubmed: 30115704
Russo, A., McCusker, M. G., Scilla, K. A., Arensmeyer, K. E., Mehra, R., Adamo, V., & Rolfo, C. (2020). Immunotherapy in lung Cancer: From a minor god to the Olympus. Advances in Experimental Medicine and Biology, 1244, 69–92. https://doi.org/10.1007/978-3-030-41008-7_4
doi: 10.1007/978-3-030-41008-7_4
pubmed: 32301011
Rossi, G., Russo, A., Tagliamento, M., Tuzi, A., Nigro, O., Vallome, G., Sini, C., Grassi, M., Dal Bello, M. G., Coco, S., Longo, L., Zullo, L., Tanda, E. T., Dellepiane, C., Pronzato, P., & Genova, C. (2020). Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the Most suitable treatment or the Most suitable patient. Cancers (Basel), 12(5). https://doi.org/10.3390/cancers12051125
Weichselbaum, R. R., Liang, H., Deng, L., & Fu, Y.-X. (2017). Radiotherapy and immunotherapy: A beneficial liaison? Nature Reviews. Clinical Oncology, 14(6), 365–379. https://doi.org/10.1038/nrclinonc.2016.211
doi: 10.1038/nrclinonc.2016.211
pubmed: 28094262
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020). Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nature Reviews. Clinical Oncology, 17(12), 725–741. https://doi.org/10.1038/s41571-020-0413-z
doi: 10.1038/s41571-020-0413-z
pubmed: 32760014
Ribas, A. (2012). Tumor immunotherapy directed at PD-1. The New England Journal of Medicine, 366(26), 2517–2519. https://doi.org/10.1056/NEJMe1205943
doi: 10.1056/NEJMe1205943
pubmed: 22658126
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews. Clinical Oncology. https://doi.org/10.1038/s41571-021-00473-5
Rimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., Fujimoto, J., Yu, H., Anders, R., Kowalewski, A., Rivard, C., Rehman, J., Batenchuk, C., Burns, V., Hirsch, F. R., & Wistuba, I. I. (2017). A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung Cancer. JAMA Oncology, 3(8), 1051–1058. https://doi.org/10.1001/jamaoncol.2017.0013
doi: 10.1001/jamaoncol.2017.0013
pubmed: 28278348
pmcid: 5650234
Marchetti, A., Barberis, M., Franco, R., De Luca, G., Pace, M. V., Staibano, S., Volante, M., Buttitta, F., Guerini-Rocco, E., Righi, L., D’antuono, T., Scagliotti, G. V., Pinto, C., De Rosa, G., & Papotti, M. (2017). Multicenter comparison of 22C3 pharm dx (Agilent) and SP263 (Ventana) assays to test PD-L1 expression for NSCLC patients to be treated with immune checkpoint inhibitors. Journal of Thoracic Oncology, 12(11), 1654–1663. https://doi.org/10.1016/j.jtho.2017.07.031
doi: 10.1016/j.jtho.2017.07.031
pubmed: 28818609
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., Mistry, A., Kalamegham, R., Averbuch, S., Novotny, J., Rubin, E., Emancipator, K., McCaffery, I., Williams, J. A., Walker, J., Longshore, J., Tsao, M. S., & Kerr, K. M. (2017). PD-L1 immunohistochemistry assays for lung Cancer: Results from phase 1 of the blueprint PD-L1 IHC assay comparison project. Journal of Thoracic Oncology, 12(2), 208–222. https://doi.org/10.1016/j.jtho.2016.11.2228
doi: 10.1016/j.jtho.2016.11.2228
pubmed: 27913228
Tsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., Chung, J.-H., Dacic, S., Lantuejoul, S., Mino-Kenudson, M., Moreira, A. L., Nicholson, A. G., Noguchi, M., Pelosi, G., Poleri, C., Russell, P. A., Sauter, J., Thunnissen, E., Wistuba, I., Yu, H., Wynes, M. W., Pintilie, M., Yatabe, Y., & Hirsch, F. R. (2018). PD-L1 immunohistochemistry comparability study in real-life clinical samples: Results of blueprint phase 2 project. Journal of Thoracic Oncology, 13(9), 1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013
doi: 10.1016/j.jtho.2018.05.013
pubmed: 29800747
pmcid: 8386299
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., Majem, M., Fidler, M. J., de Castro, G. J., Garrido, M., Lubiniecki, G. M., Shentu, Y., Im, E., Dolled-Filhart, M., & Garon, E. B. (2016). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet, 387(10027), 1540–1550. https://doi.org/10.1016/S0140-6736(15)01281-7
doi: 10.1016/S0140-6736(15)01281-7
pubmed: 26712084
Russo, A., Franchina, T., Ricciardi, G. R. R., Toscano, G., Schifano, S., Lo Certo, G., Battaglia, A., Pantò, E., Scaffidi Fonti, M., & Adamo, V. (2018). The changing scenario of 1(st) line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. Critical Reviews in Oncology/Hematology, 130, 1–12. https://doi.org/10.1016/j.critrevonc.2018.06.007
doi: 10.1016/j.critrevonc.2018.06.007
pubmed: 30196906
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Leiby, M. A., Lubiniecki, G. M., Shentu, Y., Rangwala, R., & Brahmer, J. R. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. The New England Journal of Medicine, 375(19), 1823–1833. https://doi.org/10.1056/NEJMoa1606774
doi: 10.1056/NEJMoa1606774
pubmed: 27718847
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., Özgüroğlu, M., Zou, W., Sandler, A., Enquist, I., Komatsubara, K., Deng, Y., Kuriki, H., Wen, X., McCleland, M., Mocci, S., Jassem, J., & Spigel, D. R. (2020). Atezolizumab for first-Line treatment of PD-L1-selected patients with NSCLC. The New England Journal of Medicine, 383(14), 1328–1339. https://doi.org/10.1056/NEJMoa1917346
doi: 10.1056/NEJMoa1917346
pubmed: 32997907
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., Clingan, P., Sriuranpong, V., Rizvi, N., Gao, B., Li, S., Lee, S., McGuire, K., Chen, C.-I., Makharadze, T., Paydas, S., Nechaeva, M., Seebach, F., Weinreich, D. M., Yancopoulos, G. D., Gullo, G., Lowy, I., & Rietschel, P. (2021). Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, 397(10274), 592–604. https://doi.org/10.1016/S0140-6736(21)00228-2
doi: 10.1016/S0140-6736(21)00228-2
pubmed: 33581821
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G. J., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D., & Lopes, G. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet, 393(10183), 1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7
doi: 10.1016/S0140-6736(18)32409-7
pubmed: 30955977
Mountzios, G., Remon, J., Novello, S., Blais, N., Califano, R., Cufer, T., Dingemans, A. M., Liu, S. V., Peled, N., Pennell, N. A., Reck, M., Rolfo, C., Tan, D., Vansteenkiste, J., West, H., & Besse, B. (2019). Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. Annals of Oncology, 30(11), 1686–1688. https://doi.org/10.1093/annonc/mdz295
doi: 10.1093/annonc/mdz295
pubmed: 31504132
Russo, A., De Miguel, P. D., Gunasekaran, M., Scilla, K., Lapidus, R., Cooper, B., Mehra, R., Adamo, V., Malapelle, U., & Rolfo, C. (2019). Liquid biopsy tracking of lung tumor evolutions over time. Expert Review of Molecular Diagnostics, 19(12), 1099–1108. https://doi.org/10.1080/14737159.2020.1680287
doi: 10.1080/14737159.2020.1680287
pubmed: 31608732
Huang, Q., Zhang, H., Hai, J., Socinski, M. A., Lim, E., Chen, H., & Stebbing, J. (2018). Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. Oncoimmunology, 7(12), e1396403. https://doi.org/10.1080/2162402X.2017.1396403
doi: 10.1080/2162402X.2017.1396403
pubmed: 30524878
pmcid: 6279417
Russo, A., Russano, M., Franchina, T., Migliorino, M. R., Aprile, G., Mansueto, G., Berruti, A., Falcone, A., Aieta, M., Gelibter, A., Russo, A., Barni, S., Maio, M., Martelli, O., Pantano, F., Iacono, D., Calvetti, L., Quadrini, S., Roca, E., Vasile, E., Imperatori, M., Occhipinti, M., Galvano, A., Petrelli, F., Calabrò, L., Pasquini, G., Intagliata, S., Ricciardi, G. R. R., Tonini, G., Santini, D., & Adamo, V. (2020). Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A large retrospective multicenter study. Advances in Therapy, 37(3), 1145–1155. https://doi.org/10.1007/s12325-020-01229-w
doi: 10.1007/s12325-020-01229-w
pubmed: 32002809
Howlader, N, Noone, A., Krapcho, M., Miller, D., Bishop, K., Kosary, C.L., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., Chen, H.S., Feuer, E.J., Cronin, K.A. (Eds.), SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/ , based on November 2019 SEER data submission, posted to the SEER web site, April 2019.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., Spiro, S. G., Rolland, E., Fossati, R., Aubert, D., Ding, K., Waller, D., & Le Chevalier, T. (2008). Lung adjuvant cisplatin evaluation: A pooled analysis by the LACE collaborative group. Journal of Clinical Oncology, 26(21), 3552–3559. https://doi.org/10.1200/JCO.2007.13.9030
doi: 10.1200/JCO.2007.13.9030
pubmed: 18506026
NSCLC collaborative group. (2014). Preoperative chemotherapy for non-small-cell lung cancer: A systematic review and meta-analysis of individual participant data. Lancet, 383(9928), 1561–1571. https://doi.org/10.1016/S0140-6736(13)62159-5
doi: 10.1016/S0140-6736(13)62159-5
Burdett, S., Pignon, J. P., Tierney, J., Tribodet, H., Stewart, L., Le Pechoux, C., Aupérin, A., Le Chevalier, T., Stephens, R. J., Arriagada, R., Higgins, J. P. T., Johnson, D. H., Van Meerbeeck, J., Parmar, M. K. B., Souhami, R. L., Bergman, B., Douillard, J.-Y., Dunant, A., Endo, C., Girling, D., Kato, H., Keller, S. M., Kimura, H., Knuuttila, A., Kodama, K., Komaki, R., Kris, M. G., Lad, T., Mineo, T., Piantadosi, S., Rosell, R., Scagliotti, G., Seymour, L. K., Shepherd, F. A., Sylvester, R., Tada, H., Tanaka, F., Torri, V., Waller, D., & Liang, Y. (2015). Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews, 3, CD011430. https://doi.org/10.1002/14651858.CD011430
doi: 10.1002/14651858.CD011430
Wu, Y.-L., Tsuboi, M., He, J., John, T., Grohe, C., Majem, M., Goldman, J. W., Laktionov, K., Kim, S.-W., Kato, T., Vu, H.-V., Lu, S., Lee, K.-Y., Akewanlop, C., Yu, C.-J., de Marinis, F., Bonanno, L., Domine, M., Shepherd, F. A., Zeng, L., Hodge, R., Atasoy, A., Rukazenkov, Y., & Herbst, R. S. (2020). Osimertinib in resected EGFR-mutated non-small-cell lung Cancer. The New England Journal of Medicine, 383(18), 1711–1723. https://doi.org/10.1056/NEJMoa2027071
doi: 10.1056/NEJMoa2027071
pubmed: 32955177
Ahn, M.-J., Park, S., Jung, H. A., Cho, J. H., Sun, J.-M., Lee, S.-H., Choi, Y. S., Ahn, J. S., Kim, J., Park, K., Zo, J. I., Shim, Y. M., Kim, K. H., Shin, E.-C., & Kim, H. K. (2019). Phase II, prospective single-arm study of adjuvant pembrolizumab in N2 positive non-small cell lung cancer (NSCLC) treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection: Preliminary results. JCO, 37(15_suppl), 8520–8520. https://doi.org/10.1200/JCO.2019.37.15_suppl.8520
doi: 10.1200/JCO.2019.37.15_suppl.8520
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Naidoo, J., Marrone, K. A., Verde, F., Guo, H., Zhang, J., Caushi, J. X., Chan, H. Y., Sidhom, J.-W., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R., & Pardoll, D. M. (2018). Neoadjuvant PD-1 blockade in Resectable lung Cancer. The New England Journal of Medicine, 378(21), 1976–1986. https://doi.org/10.1056/NEJMoa1716078
doi: 10.1056/NEJMoa1716078
pubmed: 29658848
pmcid: 6223617
Lee, J., Chaft, J., Nicholas, A., Patterson, A., Waqar, S., Toloza, E., Haura, E., Raz, D., Reckamp, K., Merritt, R., Owen, D., Finley, D., Mcnamee, C., Blasberg, J., Garon, E., Mitchell, J., Doebele, R., Baciewicz, F., Nagasaka, M., Pass, H., Schulze, K., Phan, S., Johnson, A., Bunn, P., Johnson, B., Kris, M., Kwiatkowski, D., Wistuba, I., Carbone, D., & Rusch, V. (2021). PS01.05 surgical and clinical outcomes with neoadjuvant Atezolizumab in Resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. Journal of Thoracic Oncology, 16(3), S59–S61. https://doi.org/10.1016/j.jtho.2021.01.320
doi: 10.1016/j.jtho.2021.01.320
Cascone, T., William, W. N. J., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., Khan, M. A. W., Dejima, H., Francisco-Cruz, A., Parra, E. R., Solis, L. M., Fujimoto, J., Tran, H. T., Kalhor, N., Fossella, F. V., Mott, F. E., Tsao, A. S., Blumenschein, G. J., Le, X., Zhang, J., Skoulidis, F., Kurie, J. M., Altan, M., Lu, C., Glisson, B. S., Byers, L. A., Elamin, Y. Y., Mehran, R. J., Rice, D. C., Walsh, G. L., Hofstetter, W. L., Roth, J. A., Antonoff, M. B., Kadara, H., Haymaker, C., Bernatchez, C., Ajami, N. J., Jenq, R. R., Sharma, P., Allison, J. P., Futreal, A., Wargo, J. A., Wistuba, I. I., Swisher, S. G., Lee, J. J., Gibbons, D. L., Vaporciyan, A. A., Heymach, J. V., & Sepesi, B. (2021). Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nature Medicine, 27(3), 504–514. https://doi.org/10.1038/s41591-020-01224-2
doi: 10.1038/s41591-020-01224-2
pubmed: 33603241
Provencio, M., Nadal, E., Insa, A., García-Campelo, M. R., Casal-Rubio, J., Dómine, M., Majem, M., Rodríguez-Abreu, D., Martínez-Martí, A., De Castro, C. J., Cobo, M., López Vivanco, G., Del Barco, E., Bernabé Caro, R., Viñolas, N., Barneto Aranda, I., Viteri, S., Pereira, E., Royuela, A., Casarrubios, M., Salas Antón, C., Parra, E. R., Wistuba, I., Calvo, V., Laza-Briviesca, R., Romero, A., Massuti, B., & Cruz-Bermúdez, A. (2020). Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): An open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology, 21(11), 1413–1422. https://doi.org/10.1016/S1470-2045(20)30453-8
doi: 10.1016/S1470-2045(20)30453-8
pubmed: 32979984
Shu, C. A., Gainor, J. F., Awad, M. M., Chiuzan, C., Grigg, C. M., Pabani, A., Garofano, R. F., Stoopler, M. B., Cheng, S. K., White, A., Lanuti, M., D’Ovidio, F., Bacchetta, M., Sonett, J. R., Saqi, A., & Rizvi, N. A. (2020). Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: An open-label, multicentre, single-arm, phase 2 trial. The Lancet Oncology, 21(6), 786–795. https://doi.org/10.1016/S1470-2045(20)30140-6
doi: 10.1016/S1470-2045(20)30140-6
pubmed: 32386568
Ready, N., Tong, B., Clarke, J., Gu, L., Wigle, D., Dragnev, K., Sporn, T., Stinchcombe, T., & D’Amico, T. (2019). P2.04-89 neoadjuvant Pembrolizumab in early stage Non-Small Cell Lung Cancer (NSCLC): Toxicity, efficacy, and surgical outcomes. Journal of Thoracic Oncology, 14(10), S745. https://doi.org/10.1016/j.jtho.2019.08.1594
doi: 10.1016/j.jtho.2019.08.1594
Bar, J., Urban, D., Ofek, E., Ackerstein, A., Redinsky, I., Golan, N., Kamer, I., Simansky, D., Onn, A., Raskin, S., Shulimzon, T., Peled, M., Zeitlin, N., Halparin, S., Jurkowicz, M., Abukhalil, R., Perelman, M., & Ben-Nun, A. (2019). Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): Updated report of a phase I study, MK3475-223. JCO, 37(15_suppl), 8534–8534. https://doi.org/10.1200/JCO.2019.37.15_suppl.8534
doi: 10.1200/JCO.2019.37.15_suppl.8534
Gao, S., Li, N., Gao, S., Xue, Q., Ying, J., Wang, S., Tao, X., Zhao, J., Mao, Y., Wang, B., Shao, K., Lei, W., Wang, D., Lv, F., Zhao, L., Zhang, F., Zhao, Z., Su, K., Tan, F., Gao, Y., Sun, N., Wu, D., Yu, Y., Ling, Y., Wang, Z., Duan, C., Tang, W., Zhang, L., He, S., Wu, N., Wang, J., & He, J. (2020). Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. Journal of Thoracic Oncology, 15(5), 816–826. https://doi.org/10.1016/j.jtho.2020.01.017
doi: 10.1016/j.jtho.2020.01.017
pubmed: 32036071
Wislez, M., Mazieres, J., Lavole, A., Zalcman, G., Carre, O., Egenod, T., Caliandro, R., Gervais, R., Jeannin, G., Molinier, O., Massiani, M. A., Langlais, A., Morin, F., Le Pimpec, B. F., Brouchet, L., Assouad, J., Milleron, B., Damotte, D., Antoine, M., & Westeel, V. (2020). 1214O neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO). Annals of Oncology, 31, S794. https://doi.org/10.1016/j.annonc.2020.08.1416
doi: 10.1016/j.annonc.2020.08.1416
Besse, B., Adam, J., Cozic, N., Chaput-Gras, N., Planchard, D., Mezquita, L., Masip, J. R., Lavaud, P., Naltet, C., Gazzah, A., Thomas de Montpreville, V., Ghigna, M.-R., Mussot, S., Fadel, E., Mabille, L., Duchemann, B., Barlesi, F., Soria, J.-C., Caramella, C., & Mercier, O. (2020). 1215O – SC Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial. Annals of Oncology, 31, S794–S795. https://doi.org/10.1016/j.annonc.2020.08.1417
doi: 10.1016/j.annonc.2020.08.1417
Zinner, R., Axelrod, R., Solomides, C. C., Cowan, S., Leiby, B., Bhatia, A. K., Sundermeyer, M. L., Hooper, D. C., Harshyne, L., Lu-Yao, G. L., Quereda-Bernabeu, B. C., Whang, S. C., OHara, S. C., Vernau, D. C., Werner-Wasik, M., Lu, B., Johnson, J. M., Scott, W. C., Argiris, A., & Evans, N. R. (2020). Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin/gemcitabine (G) in resectable NSCLC. JCO, 38(15_suppl), 9051–9051. https://doi.org/10.1200/JCO.2020.38.15_suppl.9051
doi: 10.1200/JCO.2020.38.15_suppl.9051
Yang, C.-F. J., McSherry, F., Mayne, N. R., Wang, X., Berry, M. F., Tong, B., Harpole, D. H. J., D’Amico, T. A., Christensen, J. D., Ready, N. E., & Klapper, J. A. (2018). Surgical outcomes after neoadjuvant chemotherapy and Ipilimumab for non-small cell lung Cancer. The Annals of Thoracic Surgery, 105(3), 924–929. https://doi.org/10.1016/j.athoracsur.2017.09.030
doi: 10.1016/j.athoracsur.2017.09.030
pubmed: 29258674
Rothschild, S., Zippelius, A., Eboulet, E. I., Savic, S., Betticher, D. C., Bettini, A., Frueh, M., Joerger, M., Britschgi, C., Peters, S., Mark, M. T., Ochsenbein, A., Janthur, W. D., Waibel, C., Mach, N., Gonzalez, M., Froesch, P., Godar, G., Rusterholz, C., & Pless, M. (2020). SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. JCO, 38(15_suppl), 9016–9016. https://doi.org/10.1200/JCO.2020.38.15_suppl.9016
doi: 10.1200/JCO.2020.38.15_suppl.9016
Aupérin, A., Le Péchoux, C., Pignon, J. P., Koning, C., Jeremic, B., Clamon, G., Einhorn, L., Ball, D., Trovo, M. G., Groen, H. J. M., Bonner, J. A., Le Chevalier, T., & Arriagada, R. (2006). Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Annals of Oncology, 17(3), 473–483. https://doi.org/10.1093/annonc/mdj117
doi: 10.1093/annonc/mdj117
pubmed: 16500915
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., Yamanaka, T., Bozonnat, M.-C., Uitterhoeve, A., Wang, X., Stewart, L., Arriagada, R., Burdett, S., & Pignon, J.-P. (2010). Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. Journal of Clinical Oncology, 28(13), 2181–2190. https://doi.org/10.1200/JCO.2009.26.2543
doi: 10.1200/JCO.2009.26.2543
pubmed: 20351327
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro, C. J., Faivre-Finn, C., Reck, M., Vansteenkiste, J., Spigel, D. R., Wadsworth, C., Melillo, G., Taboada, M., Dennis, P. A., & Özgüroğlu, M. (2018). Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. The New England Journal of Medicine, 379(24), 2342–2350. https://doi.org/10.1056/NEJMoa1809697
doi: 10.1056/NEJMoa1809697
pubmed: 30280658
Gray, J. E., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., Cho, B. C., Planchard, D., Paz-Ares, L., Faivre-Finn, C., Vansteenkiste, J. F., Spigel, D. R., Wadsworth, C., Taboada, M., Dennis, P. A., Özgüroğlu, M., & Antonia, S. J. (2020). Three-year overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC-update from PACIFIC. Journal of Thoracic Oncology, 15(2), 288–293. https://doi.org/10.1016/j.jtho.2019.10.002
doi: 10.1016/j.jtho.2019.10.002
pubmed: 31622733
Faivre-Finn, C., Spigel, D. R., Senan, S., Langer, C., Perez, B. A., Özgüroğlu, M., Daniel, D., Villegas, A., Vicente, D., Hui, R., Murakami, S., Paz-Ares, L., Broadhurst, H., Wadsworth, C., Dennis, P. A., & Antonia, S. J. (2021). Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable stage III NSCLC (PACIFIC). Lung Cancer, 151, 30–38. https://doi.org/10.1016/j.lungcan.2020.11.024
doi: 10.1016/j.lungcan.2020.11.024
pubmed: 33285469
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., Pitot, H. C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T. M., Alaparthy, S., Grosso, J. F., Korman, A. J., Parker, S. M., Agrawal, S., Goldberg, S. M., Pardoll, D. M., Gupta, A., & Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England Journal of Medicine, 366(26), 2455–2465. https://doi.org/10.1056/NEJMoa1200694
doi: 10.1056/NEJMoa1200694
pubmed: 22658128
pmcid: 3563263
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., & Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine, 366(26), 2443–2454. https://doi.org/10.1056/NEJMoa1200690
doi: 10.1056/NEJMoa1200690
pubmed: 22658127
pmcid: 3544539
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung Cancer. The New England Journal of Medicine, 373(2), 123–135. https://doi.org/10.1056/NEJMoa1504627
doi: 10.1056/NEJMoa1504627
pubmed: 26028407
pmcid: 4681400
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Rizvi, N., Crinò, L., Blumenschein, G. R. J., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F., & Brahmer, J. R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung Cancer. The New England Journal of Medicine, 373(17), 1627–1639. https://doi.org/10.1056/NEJMoa1507643
doi: 10.1056/NEJMoa1507643
pubmed: 26412456
pmcid: 5705936
Borghaei, H., Gettinger, S., Vokes, E. E., Chow, L. Q. M., Burgio, M. A., de Castro, C. J., Pluzanski, A., Arrieta, O., Frontera, O. A., Chiari, R., Butts, C., Wójcik-Tomaszewska, J., Coudert, B., Garassino, M. C., Ready, N., Felip, E., García, M. A., Waterhouse, D., Domine, M., Barlesi, F., Antonia, S., Wohlleber, M., Gerber, D. E., Czyzewicz, G., Spigel, D. R., Crino, L., Eberhardt, W. E. E., Li, A., Marimuthu, S., & Brahmer, J. (2021). Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung Cancer. Journal of Clinical Oncology, 39(7), 723–733. https://doi.org/10.1200/JCO.20.01605
doi: 10.1200/JCO.20.01605
pubmed: 33449799
Peters, S., Cappuzzo, F., Horn, L., Paz-Ares, L., Borghaei, H., Barlesi, F., Steins, M., Felip, E., Spigel, D., Dorange, C., Lu, H., Healey, D., Kong Sanchez, T., Bhagavatheeswaran, P., Novotny, J., Jr., Lestini, B., & Brahmer, J. (2017). OA03.05 analysis of early survival in patients with advanced non-squamous NSCLC treated with Nivolumab vs docetaxel in CheckMate 057. Journal of Thoracic Oncology, 12(1), S253. https://doi.org/10.1016/j.jtho.2016.11.241
doi: 10.1016/j.jtho.2016.11.241
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., Braiteh, F., Waterkamp, D., He, P., Zou, W., Chen, D. S., Yi, J., Sandler, A., & Rittmeyer, A. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387(10030), 1837–1846. https://doi.org/10.1016/S0140-6736(16)00587-0
doi: 10.1016/S0140-6736(16)00587-0
pubmed: 26970723
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., Cortinovis, D. L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O. A., De Marinis, F., Turna, H., Lee, J.-S., Ballinger, M., Kowanetz, M., He, P., Chen, D. S., Sandler, A., & Gandara, D. R. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet, 389(10066), 255–265. https://doi.org/10.1016/S0140-6736(16)32517-X
doi: 10.1016/S0140-6736(16)32517-X
pubmed: 27979383
Mazieres, J., Rittmeyer, A., Gadgeel, S., Hida, T., Gandara, D. R., Cortinovis, D. L., Barlesi, F., Yu, W., Matheny, C., Ballinger, M., & Park, K. (2021). Atezolizumab versus docetaxel in pretreated patients with NSCLC: Final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. Journal of Thoracic Oncology, 16(1), 140–150. https://doi.org/10.1016/j.jtho.2020.09.022
doi: 10.1016/j.jtho.2020.09.022
pubmed: 33166718
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.-J., Felip, E., Lee, J.-S., Hellmann, M. D., Hamid, O., Goldman, J. W., Soria, J.-C., Dolled-Filhart, M., Rutledge, R. Z., Zhang, J., Lunceford, J. K., Rangwala, R., Lubiniecki, G. M., Roach, C., Emancipator, K., & Gandhi, L. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine, 372(21), 2018–2028. https://doi.org/10.1056/NEJMoa1501824
doi: 10.1056/NEJMoa1501824
pubmed: 25891174
Herbst, R. S., Garon, E. B., Kim, D.-W., Cho, B. C., Perez-Gracia, J. L., Han, J.-Y., Arvis, C. D., Majem, M., Forster, M. D., Monnet, I., Novello, S., Szalai, Z., Gubens, M. A., Su, W.-C., Ceresoli, G. L., Samkari, A., Jensen, E. H., Lubiniecki, G. M., & Baas, P. (2020). Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1–positive, advanced non–small-cell lung Cancer in the KEYNOTE-010 study. Journal of Clinical Oncology, 38(14), 1580–1590. https://doi.org/10.1200/JCO.19.02446
doi: 10.1200/JCO.19.02446
pubmed: 32078391
Barlesi, F., Vansteenkiste, J., Spigel, D., Ishii, H., Garassino, M., de Marinis, F., Özgüroğlu, M., Szczesna, A., Polychronis, A., Uslu, R., Krzakowski, M., Lee, J.-S., Calabrò, L., Arén Frontera, O., Ellers-Lenz, B., Bajars, M., Ruisi, M., & Park, K. (2018). Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): An open-label, randomised, phase 3 study. The Lancet Oncology, 19(11), 1468–1479. https://doi.org/10.1016/S1470-2045(18)30673-9
doi: 10.1016/S1470-2045(18)30673-9
pubmed: 30262187
Tan, P. S., Aguiar, P. J., Haaland, B., & Lopes, G. (2018). Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – a systematic review and network meta-analysis of 3024 participants. Lung Cancer, 115, 84–88. https://doi.org/10.1016/j.lungcan.2017.11.017
doi: 10.1016/j.lungcan.2017.11.017
pubmed: 29290267
Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018). Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis. JAMA Oncology, 4(2), 210–216. https://doi.org/10.1001/jamaoncol.2017.4427
doi: 10.1001/jamaoncol.2017.4427
pubmed: 29270615
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O’Brien, M., Rao, S., Hotta, K., Vandormael, K., Riccio, A., Yang, J., Pietanza, M. C., & Brahmer, J. R. (2019). Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung Cancer with PD-L1 tumor proportion score of 50% or greater. Journal of Clinical Oncology, 37(7), 537–546. https://doi.org/10.1200/JCO.18.00149
doi: 10.1200/JCO.18.00149
pubmed: 30620668
Aguilar, E. J., Ricciuti, B., Gainor, J. F., Kehl, K. L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L. M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R. M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K. C., Carter, B. W., Heymach, J. V., Altan, M., Hellmann, M. D., & Awad, M. M. (2019). Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Annals of Oncology, 30(10), 1653–1659. https://doi.org/10.1093/annonc/mdz288
doi: 10.1093/annonc/mdz288
pubmed: 31435660
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., Ready, N., Hiltermann, T. J. N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J. M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G. R. J., Villaruz, L. C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W. J., Bhagavatheeswaran, P., Chen, A. C., & Socinski, M. A. (2017). First-Line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. The New England Journal of Medicine, 376(25), 2415–2426. https://doi.org/10.1056/NEJMoa1613493
doi: 10.1056/NEJMoa1613493
pubmed: 28636851
pmcid: 6487310
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., Cheng, S. Y.-S., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Boyer, M., Rubio-Viqueira, B., Novello, S., Kurata, T., Gray, J. E., Vida, J., Wei, Z., Yang, J., Raftopoulos, H., Pietanza, M. C., & Garassino, M. C. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung Cancer. The New England Journal of Medicine, 378(22), 2078–2092. https://doi.org/10.1056/NEJMoa1801005
doi: 10.1056/NEJMoa1801005
pubmed: 29658856
Gadgeel, S., Rodríguez-Abreu, D., Speranza, G., Esteban, E., Felip, E., Dómine, M., Hui, R., Hochmair, M. J., Clingan, P., Powell, S. F., Cheng, S. Y.-S., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Garon, E. B., Novello, S., Rubio-Viqueira, B., Boyer, M., Kurata, T., Gray, J. E., Yang, J., Bas, T., Pietanza, M. C., & Garassino, M. C. (2020). Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus Pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung Cancer. Journal of Clinical Oncology, 38(14), 1505–1517. https://doi.org/10.1200/JCO.19.03136
doi: 10.1200/JCO.19.03136
pubmed: 32150489
Gray, J., Rodríguez-Abreu, D., Powell, S. F., Hochmair, M. J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S. Y., Bischoff, H. G., Peled, N., Reck, M., Hui, R., Garon, E. B., Boyer, M., Kurata, T., Yang, J., Jensen, E., Souza, F., & Garassino, M. C. (2021). FP13.02 Pembrolizumab + Pemetrexed-platinum vs Pemetrexed-platinum for metastatic NSCLC: 4-year follow-up from KEYNOTE-189. Journal of Thoracic Oncology, 16(3), S224. https://doi.org/10.1016/j.jtho.2021.01.141
doi: 10.1016/j.jtho.2021.01.141
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., Rodríguez-Cid, J., Wilson, J., Sugawara, S., Kato, T., Lee, K. H., Cheng, Y., Novello, S., Halmos, B., Li, X., Lubiniecki, G. M., Piperdi, B., & Kowalski, D. M. (2018). Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer. The New England Journal of Medicine, 379(21), 2040–2051. https://doi.org/10.1056/NEJMoa1810865
doi: 10.1056/NEJMoa1810865
pubmed: 30280635
Borghaei, H., Langer, C. J., Paz-Ares, L., Rodríguez-Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., Pietanza, M. C., Piperdi, B., & Gadgeel, S. M. (2020). Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer, 126(22), 4867–4877. https://doi.org/10.1002/cncr.33142
doi: 10.1002/cncr.33142
pubmed: 32914866
Robinson, A. G., Vicente, D., Tafreshi, A., Parra, H. S., Mazieres, J., Cicin, I., Medgyasszay, B., Rodríguez-Cid, J., Okamoto, I., Lee, S., Ramlau, R., Vladimirov, V., Cheng, Y., Halmos, B., Liu, C.-C., Schwarzenberger, P., Piperdi, B., & Paz-Ares, L. (2021). 97O first-line pembrolizumab plus chemotherapy for patients with advanced squamous NSCLC: 3-year follow-up from KEYNOTE-407. Journal of Thoracic Oncology, 16(4), S748–S749. https://doi.org/10.1016/S1556-0864(21)01939-0
doi: 10.1016/S1556-0864(21)01939-0
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Kelsch, C., Lee, A., Coleman, S., Deng, Y., Shen, Y., Kowanetz, M., Lopez-Chavez, A., Sandler, A., & Reck, M. (2018). Atezolizumab for first-Line treatment of metastatic nonsquamous NSCLC. The New England Journal of Medicine, 378(24), 2288–2301. https://doi.org/10.1056/NEJMoa1716948
doi: 10.1056/NEJMoa1716948
pubmed: 29863955
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., Finley, G., Lee, A., Coleman, S., Deng, Y., Kowanetz, M., Shankar, G., Lin, W., & Socinski, M. A. (2019). Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. The Lancet Respiratory Medicine, 7(5), 387–401. https://doi.org/10.1016/S2213-2600(19)30084-0
doi: 10.1016/S2213-2600(19)30084-0
pubmed: 30922878
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., Zer, A., Reinmuth, N., Sadiq, A., Sandler, A., Lin, W., Ochi Lohmann, T., Archer, V., Wang, L., Kowanetz, M., & Cappuzzo, F. (2019). Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology, 20(7), 924–937. https://doi.org/10.1016/S1470-2045(19)30167-6
doi: 10.1016/S1470-2045(19)30167-6
pubmed: 31122901
Jotte, R., Cappuzzo, F., Vynnychenko, I., Stroyakovskiy, D., Rodríguez-Abreu, D., Hussein, M., Soo, R., Conter, H. J., Kozuki, T., Huang, K.-C., Graupner, V., Sun, S. W., Hoang, T., Jessop, H., McCleland, M., Ballinger, M., Sandler, A., & Socinski, M. A. (2020). Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. Journal of Thoracic Oncology, 15(8), 1351–1360. https://doi.org/10.1016/j.jtho.2020.03.028
doi: 10.1016/j.jtho.2020.03.028
pubmed: 32302702
Nishio, M., Barlesi, F., West, H., Ball, S., Bordoni, R., Cobo, M., Longeras, P. D., Goldschmidt, J., Jr., Novello, S., Orlandi, F., Sanborn, R. E., Szalai, Z., Ursol, G., Mendus, D., Wang, L., Wen, X., McCleland, M., Hoang, T., Phan, S., & Socinski, M. A. (2021). Atezolizumab plus chemotherapy for first-Line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial. Journal of Thoracic Oncology, 16(4), 653–664. https://doi.org/10.1016/j.jtho.2020.11.025
doi: 10.1016/j.jtho.2020.11.025
pubmed: 33333328
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora, J. E., Sakai, H., Albert, I., Vergnenegre, A., Peters, S., Syrigos, K., Barlesi, F., Reck, M., Borghaei, H., Brahmer, J. R., O’Byrne, K. J., Geese, W. J., Bhagavatheeswaran, P., Rabindran, S. K., Kasinathan, R. S., Nathan, F. E., & Ramalingam, S. S. (2019). Nivolumab plus Ipilimumab in advanced non-small-cell lung Cancer. The New England Journal of Medicine, 381(21), 2020–2031. https://doi.org/10.1056/NEJMoa1910231
doi: 10.1056/NEJMoa1910231
pubmed: 31562796
Ramalingam, S. S., Ciuleanu, T. E., Pluzanski, A., Lee, J.-S., Schenker, M., Bernabe Caro, R., Lee, K. H., Zurawski, B., Audigier-Valette, C., Provencio, M., Linardou, H., Kim, S.-W., Borghaei, H., Hellmann, M. D., O’Byrne, K. J., Paz-Ares, L. G., Reck, M., Nathan, F. E., & Brahmer, J. R. (2020). Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. JCO, 38(15_suppl), 9500–9500. https://doi.org/10.1200/JCO.2020.38.15_suppl.9500
doi: 10.1200/JCO.2020.38.15_suppl.9500
Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., Moiseyenko, V., Antonia, S. J., Le Moulec, S., Robinet, G., Natale, R., Schneider, J., Shepherd, F. A., Geater, S. L., Garon, E. B., Kim, E. S., Goldberg, S. B., Nakagawa, K., Raja, R., Higgs, B. W., Boothman, A.-M., Zhao, L., Scheuring, U., Stockman, P. K., Chand, V. K., & Peters, S. (2020). Durvalumab with or without Tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung Cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncology, 6(5), 661–674. https://doi.org/10.1001/jamaoncol.2020.0237
doi: 10.1001/jamaoncol.2020.0237
pubmed: 32271377
pmcid: 7146551
Si, H., Kuziora, M., Quinn, K. J., Helman, E., Ye, J., Liu, F., Scheuring, U., Peters, S., Rizvi, N. A., Brohawn, P. Z., Ranade, K., Higgs, B. W., Banks, K. C., Chand, V. K., & Raja, R. (2021). A blood-based assay for assessment of tumor mutational burden in first-line metastatic NSCLC treatment: Results from the MYSTIC study. Clinical Cancer Research, 27(6), 1631–1640. https://doi.org/10.1158/1078-0432.CCR-20-3771
doi: 10.1158/1078-0432.CCR-20-3771
pubmed: 33355200
Boyer, M., Şendur, M. A. N., Rodríguez-Abreu, D., Park, K., Lee, D. H., Çiçin, I., Yumuk, P. F., Orlandi, F. J., Leal, T. A., Molinier, O., Soparattanapaisarn, N., Langleben, A., Califano, R., Medgyasszay, B., Hsia, T.-C., Otterson, G. A., Xu, L., Piperdi, B., Samkari, A., & Reck, M. (2021). Pembrolizumab plus Ipilimumab or placebo for metastatic non-small-cell lung Cancer with PD-L1 tumor proportion score ≥ 50%: Randomized, double-blind phase III KEYNOTE-598 study. Journal of Clinical Oncology, JCO2003579. https://doi.org/10.1200/JCO.20.03579
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Lingua, A., Salman, P., Souquet, P.-J., De Marchi, P., Martin, C., Pérol, M., Scherpereel, A., Lu, S., John, T., Carbone, D. P., Meadows-Shropshire, S., Agrawal, S., Oukessou, A., Yan, J., & Reck, M. (2021). First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. The Lancet Oncology, 22(2), 198–211. https://doi.org/10.1016/S1470-2045(20)30641-0
doi: 10.1016/S1470-2045(20)30641-0
pubmed: 33476593
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Scherpereel, A., Reck, M., Lu, S., John, T., Meadows-Shropshire, S., Balli, D., Agrawal, S., & Carbone, D. P. (2021). 98O first-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA. Journal of Thoracic Oncology, 16(4), S750–S751. https://doi.org/10.1016/S1556-0864(21)01940-7
doi: 10.1016/S1556-0864(21)01940-7
Bernhardt, E. B., & Jalal, S. I. (2016). Small Cell Lung Cancer. Cancer Treatment and Research, 170, 301–322. https://doi.org/10.1007/978-3-319-40389-2_14
doi: 10.1007/978-3-319-40389-2_14
pubmed: 27535400
Denninghoff, V., Russo, A., de Miguel-Pérez, D., Malapelle, U., Benyounes, A., Gittens, A., Cardona, A. F., & Rolfo, C. (2021). Small cell lung Cancer: State of the art of the molecular and genetic landscape and novel perspective. Cancers, 13(7). https://doi.org/10.3390/cancers13071723
Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021). Small-cell lung cancer. Nature Reviews. Disease Primers, 7(1), 3. https://doi.org/10.1038/s41572-020-00235-0
doi: 10.1038/s41572-020-00235-0
pubmed: 33446664
pmcid: 8177722
Armstrong, S. A., & Liu, S. V. (2020). Dashing decades of defeat: Long anticipated advances in the first-line treatment of extensive-stage small cell lung Cancer. Current Oncology Reports, 22(2), 20. https://doi.org/10.1007/s11912-020-0887-y
doi: 10.1007/s11912-020-0887-y
pubmed: 32034529
Schultheis, A. M., Scheel, A. H., Ozretić, L., George, J., Thomas, R. K., Hagemann, T., Zander, T., Wolf, J., & Buettner, R. (2015). PD-L1 expression in small cell neuroendocrine carcinomas. European Journal of Cancer, 51(3), 421–426. https://doi.org/10.1016/j.ejca.2014.12.006
doi: 10.1016/j.ejca.2014.12.006
pubmed: 25582496
Iams, W. T., Shiuan, E., Meador, C. B., Roth, M., Bordeaux, J., Vaupel, C., Boyd, K. L., Summitt, I. B., Wang, L. L., Schneider, J. T., Warner, J. L., Zhao, Z., & Lovly, C. M. (2019). Improved prognosis and increased tumor-infiltrating lymphocytes in patients who have SCLC with neurologic paraneoplastic syndromes. Journal of Thoracic Oncology, 14(11), 1970–1981. https://doi.org/10.1016/j.jtho.2019.05.042
doi: 10.1016/j.jtho.2019.05.042
pubmed: 31201935
pmcid: 6823126
Bonanno, L., Pavan, A., Dieci, M. V., Di Liso, E., Schiavon, M., Comacchio, G., Attili, I., Pasello, G., Calabrese, F., Rea, F., Favaretto, A., Rugge, M., Guarneri, V., Fassan, M., & Conte, P. F. (2018). The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. European Journal of Cancer, 101, 191–200. https://doi.org/10.1016/j.ejca.2018.06.023
doi: 10.1016/j.ejca.2018.06.023
pubmed: 30077124
Berghoff, A. S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K., Birner, P., Bartsch, R., & Preusser, M. (2016). Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). Journal of Neuro-Oncology, 130(1), 19–29. https://doi.org/10.1007/s11060-016-2216-8
doi: 10.1007/s11060-016-2216-8
pubmed: 27436101
Reck, M., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Lu, H., Cuillerot, J.-M., & Lynch, T. J. (2013). Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology, 24(1), 75–83. https://doi.org/10.1093/annonc/mds213
doi: 10.1093/annonc/mds213
pubmed: 22858559
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., Felip, E., Gold, K., Horn, L., Aerts, J., Nakagawa, K., Lorigan, P., Pieters, A., Kong Sanchez, T., Fairchild, J., & Spigel, D. (2016). Phase III randomized trial of Ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung Cancer. Journal of Clinical Oncology, 34(31), 3740–3748. https://doi.org/10.1200/JCO.2016.67.6601
doi: 10.1200/JCO.2016.67.6601
pubmed: 27458307
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., Reck, M., Mok, T., Lam, S., Shames, D. S., Liu, J., Ding, B., Lopez-Chavez, A., Kabbinavar, F., Lin, W., Sandler, A., & Liu, S. V. (2018). First-Line Atezolizumab plus chemotherapy in extensive-stage small-cell lung Cancer. The New England Journal of Medicine, 379(23), 2220–2229. https://doi.org/10.1056/NEJMoa1809064
doi: 10.1056/NEJMoa1809064
pubmed: 30280641
Liu, S. V., Reck, M., Mansfield, A. S., Mok, T., Scherpereel, A., Reinmuth, N., Garassino, M. C., De Castro, C. J., Califano, R., Nishio, M., Orlandi, F., Alatorre-Alexander, J., Leal, T., Cheng, Y., Lee, J.-S., Lam, S., McCleland, M., Deng, Y., Phan, S., & Horn, L. (2021). Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with Atezolizumab, carboplatin, and etoposide (IMpower133). Journal of Clinical Oncology, 39(6), 619–630. https://doi.org/10.1200/JCO.20.01055
doi: 10.1200/JCO.20.01055
pubmed: 33439693
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Kazarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Shire, N., Jiang, H., & Goldman, J. W. (2019). Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet, 394(10212), 1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6
doi: 10.1016/S0140-6736(19)32222-6
pubmed: 31590988
Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Garassino, M. C., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Thiyagarajah, P., Jiang, H., & Paz-Ares, L. (2021). Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 22(1), 51–65. https://doi.org/10.1016/S1470-2045(20)30539-8
doi: 10.1016/S1470-2045(20)30539-8
pubmed: 33285097
Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., Mazieres, J., Orlandi, F. J., Luft, A., Gümüş, M., Kato, T., Kalemkerian, G. P., Luo, Y., Ebiana, V., Pietanza, M. C., & Kim, H. R. (2020). Pembrolizumab or placebo plus etoposide and platinum as first-Line therapy for extensive-stage small-cell lung Cancer: Randomized, double-blind, phase III KEYNOTE-604 study. Journal of Clinical Oncology, 38(21), 2369–2379. https://doi.org/10.1200/JCO.20.00793
doi: 10.1200/JCO.20.00793
pubmed: 32468956
pmcid: 7474472
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., Eder, J. P., Steele, N. L., Pieters, A., Fairchild, J., & Antonia, S. J. (2019). Third-Line Nivolumab monotherapy in recurrent SCLC: CheckMate 032. Journal of Thoracic Oncology, 14(2), 237–244. https://doi.org/10.1016/j.jtho.2018.10.003
doi: 10.1016/j.jtho.2018.10.003
pubmed: 30316010
Ready, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., Salvagni, S., Taylor, M., Amin, A., Camidge, D. R., Horn, L., Calvo, E., Li, A., Lin, W. H., Callahan, M. K., & Spigel, D. R. (2020). Nivolumab monotherapy and Nivolumab plus Ipilimumab in recurrent small cell lung Cancer: Results from the CheckMate 032 randomized cohort. Journal of Thoracic Oncology, 15(3), 426–435. https://doi.org/10.1016/j.jtho.2019.10.004
doi: 10.1016/j.jtho.2019.10.004
pubmed: 31629915
Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., Zhang, H., Shi, M., Luft, A., Wolf, J., Antonia, S., Nakagawa, K., Fairchild, J., Baudelet, C., Pandya, D., Doshi, P., Chang, H., & Reck, M. (2021). Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(☆). Annals of Oncology. https://doi.org/10.1016/j.annonc.2021.01.071
Ott, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017). Pembrolizumab in patients with extensive-stage small-cell lung Cancer: Results from the phase Ib KEYNOTE-028 study. Journal of Clinical Oncology, 35(34), 3823–3829. https://doi.org/10.1200/JCO.2017.72.5069
doi: 10.1200/JCO.2017.72.5069
pubmed: 28813164
Chung, H. C., Lopez-Martin, J. A., Kao, S. C.-H., Miller, W. H., Ros, W., Gao, B., Marabelle, A., Gottfried, M., Zer, A., Delord, J.-P., Penel, N., Jalal, S. I., Xu, L., Zeigenfuss, S., Pruitt, S. K., & Piha-Paul, S. A. (2018). Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. JCO, 36(15_suppl), 8506–8506. https://doi.org/10.1200/JCO.2018.36.15_suppl.8506
doi: 10.1200/JCO.2018.36.15_suppl.8506
Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H. J., Delord, J.-P., Gao, B., Planchard, D., Gottfried, M., Zer, A., Jalal, S. I., Penel, N., Mehnert, J. M., Matos, I., Bennouna, J., Kim, D.-W., Xu, L., Krishnan, S., Norwood, K., & Ott, P. A. (2020). Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: Results from the KEYNOTE-028 and KEYNOTE-158 studies. Journal of Thoracic Oncology, 15(4), 618–627. https://doi.org/10.1016/j.jtho.2019.12.109
doi: 10.1016/j.jtho.2019.12.109
pubmed: 31870883
Pujol, J.-L., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., Guisier, F., Carmier, D., Madelaine, J., Otto, J., Gounant, V., Merle, P., Mourlanette, P., Molinier, O., Renault, A., Rabeau, A., Antoine, M., Denis, M. G., Bommart, S., Langlais, A., Morin, F., & Souquet, P.-J. (2019). A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 Atezolizumab or chemotherapy as second-Line therapy in patients with small cell lung Cancer: Results from the IFCT-1603 trial. Journal of Thoracic Oncology, 14(5), 903–913. https://doi.org/10.1016/j.jtho.2019.01.008
doi: 10.1016/j.jtho.2019.01.008
pubmed: 30664989
Facchinetti, F., Mazzaschi, G., Barbieri, F., Passiglia, F., Mazzoni, F., Berardi, R., Proto, C., Cecere, F. L., Pilotto, S., Scotti, V., Rossi, S., Del Conte, A., Vita, E., Bennati, C., Ardizzoni, A., Cerea, G., Migliorino, M. R., Sala, E., Camerini, A., Bearz, A., De Carlo, E., Zanelli, F., Guaitoli, G., Garassino, M. C., Ciccone, L. P., Sartori, G., Toschi, L., Dall’Olio, F. G., Landi, L., Pizzutilo, E. G., Bartoli, G., Baldessari, C., Novello, S., Bria, E., Cortinovis, D. L., Rossi, G., Rossi, A., Banna, G. L., Camisa, R., Di Maio, M., & Tiseo, M. (2020). First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. European Journal of Cancer, 130, 155–167. https://doi.org/10.1016/j.ejca.2020.02.023
doi: 10.1016/j.ejca.2020.02.023
pubmed: 32220780
Hajjar, J. (2019). Cancer immunotherapy for the immunosuppressed: Dissecting the conundrum of safety and efficacy. Journal of Immunotherapy and Precision Oncology, 2(3), 53–54. https://doi.org/10.4103/JIPO.JIPO_15_19
doi: 10.4103/JIPO.JIPO_15_19
Uldrick, T. S., Gonçalves, P. H., Abdul-Hay, M., Claeys, A. J., Emu, B., Ernstoff, M. S., Fling, S. P., Fong, L., Kaiser, J. C., Lacroix, A. M., Lee, S. Y., Lundgren, L. M., Lurain, K., Parsons, C. H., Peeramsetti, S., Ramaswami, R., Sharon, E., Sznol, M., Wang, C.-C. J., Yarchoan, R., & Cheever, M. A. (2019). Assessment of the safety of Pembrolizumab in patients with HIV and advanced Cancer-a phase 1 study. JAMA Oncology, 5(9), 1332–1339. https://doi.org/10.1001/jamaoncol.2019.2244
doi: 10.1001/jamaoncol.2019.2244
pubmed: 31154457
pmcid: 6547135
Scilla, K. A., Russo, A., & Rolfo, C. (2019). Immunotherapy use in patients with HIV and non-small-cell lung Cancer: Current data. Journal of Immunotherapy and Precision Oncology, 2(3), 55–58. https://doi.org/10.4103/JIPO.JIPO_13_19
doi: 10.4103/JIPO.JIPO_13_19
Cortellini, A., Buti, S., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Bersanelli, M., Michiara, M., Grassadonia, A., Brocco, D., Tinari, N., De Tursi, M., Zoratto, F., Veltri, E., Marconcini, R., Malorgio, F., Garufi, C., Russano, M., Anesi, C., Zeppola, T., Filetti, M., Marchetti, P., Botticelli, A., Antonini Cappellini, G. C., De Galitiis, F., Vitale, M. G., Sabbatini, R., Bracarda, S., Berardi, R., Rinaldi, S., Tudini, M., Silva, R. R., Pireddu, A., Atzori, F., Chiari, R., Ricciuti, B., Iacono, D., Migliorino, M. R., Rossi, A., Porzio, G., Cannita, K., Ciciarelli, V., Fargnoli, M. C., Ascierto, P. A., & Ficorella, C. (2019). Clinical outcomes of patients with advanced Cancer and pre-existing autoimmune diseases treated with anti-programmed Death-1 immunotherapy: A real-world transverse study. The Oncologist, 24(6), e327–e337. https://doi.org/10.1634/theoncologist.2018-0618
doi: 10.1634/theoncologist.2018-0618
pubmed: 30796151
pmcid: 6656514
Leonardi, G. C., Gainor, J. F., Altan, M., Kravets, S., Dahlberg, S. E., Gedmintas, L., Azimi, R., Rizvi, H., Riess, J. W., Hellmann, M. D., & Awad, M. M. (2018). Safety of programmed Death-1 pathway inhibitors among patients with non-small-cell lung Cancer and preexisting autoimmune disorders. Journal of Clinical Oncology, 36(19), 1905–1912. https://doi.org/10.1200/JCO.2017.77.0305
doi: 10.1200/JCO.2017.77.0305
pubmed: 29746230
pmcid: 6553840
Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric-Bernstam, F., & Hwu, P. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001754
Smedman, T. M., Line, P.-D., Guren, T. K., & Dueland, S. (2018). Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients. Acta Oncologica, 57(10), 1414–1418. https://doi.org/10.1080/0284186X.2018.1479069
doi: 10.1080/0284186X.2018.1479069
pubmed: 29912605
Fisher, J., Zeitouni, N., Fan, W., & Samie, F. H. (2020). Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. Journal of the American Academy of Dermatology, 82(6), 1490–1500. https://doi.org/10.1016/j.jaad.2019.07.005
doi: 10.1016/j.jaad.2019.07.005
pubmed: 31302190
Barlesi, F., Audigier-Valette, C., Felip, E., Ciuleanu, T.-E., Jao, K., Rijavec, E., Urban, L., Aucoin, J.-S., Zannori, C., Vermaelen, K., Frontera, O. A., Ready, N., Curioni, A., Linardou, H., Poddubskaya, E., Fischer, J. R., Pillai, R., Li, S., Acevedo, A., & Paz-Ares, L. (2019). Nivolumab plus low-dose IPILIMUMAB as first-Line treatment of advanced NSCLC: Overall survival analysis of Checkmate 817. Annals of Oncology, 30, xi33–xi34. https://doi.org/10.1093/annonc/mdz451.001
doi: 10.1093/annonc/mdz451.001
Ardizzoni, A., Azevedo, S., Rubio Viquiera, B., Rodriguez Abreu, D., Alatorre-Alexander, J., Smit, H. J., Yu, J., Syrigos, K., Patel, H., Tolson, J., Cardona, A., Perez Moreno, P., & Newsom-Davis, T. (2019). LBA84 – primary results from TAIL, a global single-arm safety study of atezolizumab (atezo) monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology, 30, v920–v921. https://doi.org/10.1093/annonc/mdz394.082
doi: 10.1093/annonc/mdz394.082
Russo, A., Lopes, A. R., McCusker, M. G., Garrigues, S. G., Ricciardi, G. R., Arensmeyer, K. E., Scilla, K. A., Mehra, R., & Rolfo, C. (2020). New targets in lung Cancer (excluding EGFR, ALK, ROS1). Current Oncology Reports, 22(5), 48. https://doi.org/10.1007/s11912-020-00909-8
doi: 10.1007/s11912-020-00909-8
pubmed: 32296961
Gandara, D. R., Paul, S. M., Kowanetz, M., Schleifman, E., Zou, W., Li, Y., Rittmeyer, A., Fehrenbacher, L., Otto, G., Malboeuf, C., Lieber, D. S., Lipson, D., Silterra, J., Amler, L., Riehl, T., Cummings, C. A., Hegde, P. S., Sandler, A., Ballinger, M., Fabrizio, D., Mok, T., & Shames, D. S. (2018). Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine, 24(9), 1441–1448. https://doi.org/10.1038/s41591-018-0134-3
doi: 10.1038/s41591-018-0134-3
pubmed: 30082870
Herbst, R. S., Lopes, G., Kowalski, D. M., Nishio, M., Wu, Y.-L., de Castro, J. G., Baas, P., Kim, D.-W., Gubens, M. A., Cristescu, R., Aurora-Garg, D., Albright, A., Ayers, M., Loboda, A., Lunceford, J., Kobie, J., Lubiniecki, G. M., Pietanza, M. C., Piperdi, B., & Mok, T. S. K. (2019). Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Annals of Oncology, 30, v916–v917. https://doi.org/10.1093/annonc/mdz394.077
doi: 10.1093/annonc/mdz394.077
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H. J., Italiano, A., Kao, S., Piha-Paul, S. A., Delord, J.-P., McWilliams, R. R., Fabrizio, D. A., Aurora-Garg, D., Xu, L., Jin, F., Norwood, K., & Bang, Y.-J. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. The Lancet Oncology, 21(10), 1353–1365. https://doi.org/10.1016/S1470-2045(20)30445-9
doi: 10.1016/S1470-2045(20)30445-9
pubmed: 32919526
Paz-Ares, L., Langer, C. J., Novello, S., Halmos, B., Cheng, Y., Gadgeel, S. M., Hui, R., Sugawara, S., Borghaei, H., Cristescu, R., Aurora-Garg, D., Albright, A., Loboda, A., Kobie, J., Lunceford, J., Ayers, M., Lubiniecki, G. M., Pietanza, M. C., Piperdi, B., & Garassino, M. C. (2019). LBA80 – Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407. Annals of Oncology, 30, v917–v918. https://doi.org/10.1093/annonc/mdz394.078
doi: 10.1093/annonc/mdz394.078
Garassino, M. C., Gadgeel, S. M., Rodriguez-Abreu, D., Felip, E., Esteban, E., Speranza, G., Hochmair, M., Powell, S. F., Garon, E. B., Hui, R., Nogami, N., Cristescu, R., Morrissey, M., Loboda, A., Kobie, J., Ayers, M., Piperdi, B., Pietanza, M. C., Snyder, A., & Reck, M. (2020). Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC. JCO, 38(15_suppl), 9521–9521. https://doi.org/10.1200/JCO.2020.38.15_suppl.9521
doi: 10.1200/JCO.2020.38.15_suppl.9521
Biton, J., Mansuet-Lupo, A., Pécuchet, N., Alifano, M., Ouakrim, H., Arrondeau, J., Boudou-Rouquette, P., Goldwasser, F., Leroy, K., Goc, J., Wislez, M., Germain, C., Laurent-Puig, P., Dieu-Nosjean, M.-C., Cremer, I., Herbst, R., Blons, H., & Damotte, D. (2018). TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma. Clinical Cancer Research, 24(22), 5710–5723. https://doi.org/10.1158/1078-0432.CCR-18-0163
doi: 10.1158/1078-0432.CCR-18-0163
pubmed: 29764856
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V. (2018). STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discovery, 8(7), 822–835. https://doi.org/10.1158/2159-8290.CD-18-0099
doi: 10.1158/2159-8290.CD-18-0099
pubmed: 29773717
pmcid: 6030433
Lamberti, G., Spurr, L. F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. L., Cherniack, A. D., & Awad, M. M. (2020). Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Annals of Oncology, 31(6), 807–814. https://doi.org/10.1016/j.annonc.2020.02.017
doi: 10.1016/j.annonc.2020.02.017
pubmed: 32171752
Marinelli, D., Mazzotta, M., Scalera, S., Terrenato, I., Sperati, F., D’Ambrosio, L., Pallocca, M., Corleone, G., Krasniqi, E., Pizzuti, L., Barba, M., Carpano, S., Vici, P., Filetti, M., Giusti, R., Vecchione, A., Occhipinti, M., Gelibter, A., Botticelli, A., De Nicola, F., Ciuffreda, L., Goeman, F., Gallo, E., Visca, P., Pescarmona, E., Fanciulli, M., De Maria, R., Marchetti, P., Ciliberto, G., & Maugeri-Saccà, M. (2020). KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Annals of Oncology, 31(12), 1746–1754. https://doi.org/10.1016/j.annonc.2020.08.2105
doi: 10.1016/j.annonc.2020.08.2105
pubmed: 32866624
Rizvi, N., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M., Papadimitrakopoulou, V., Heymach, J., Scheuring, U., Higgs, B., Ye, J., Kuziora, M., Wu, S., Liu, F., Si, H., & Peters, S. (2019). OA04.07 mutations associated with sensitivity or resistance to immunotherapy in mNSCLC: Analysis from the MYSTIC trial. Journal of Thoracic Oncology, 14(10), S217. https://doi.org/10.1016/j.jtho.2019.08.428
doi: 10.1016/j.jtho.2019.08.428
Krishnamurthy, N., Goodman, A. M., Barkauskas, D. A., & Kurzrock, R. (2021). STK11 alterations in the pan-cancer setting: Prognostic and therapeutic implications. European Journal of Cancer, 148, 215–229. https://doi.org/10.1016/j.ejca.2021.01.050
doi: 10.1016/j.ejca.2021.01.050
pubmed: 33744718
Skoulidis, F., Arbour, K., Hellmann, M., Patil, P., Marmarelis, M., Owen, D., Awad, M., Murray, J., Levy, B., Hellyer, J., Gainor, J., Stewart, T., Goldberg, S., Dimou, A., Bestvina, C., Cummings, A., Elamin, Y., Lam, V., Zhang, J., Shu, C., Riess, J., Blakely, C., Pecot, C., Mezquita, L., Tabbò, F., Sacher, A., Scheffler, M., Ricciuti, B., Venkatraman, D., Rizvi, H., Liu, C., Johnston, R., Ni, Y., Azok, J., Kier, M., Katz, S., Davies, K., Segal, J., Ritterhouse, L., Shaish, H., Lacroix, L., Memmott, R., Madrigal, J., Goldman, J., Lau, S., Killam, J., Walther, Z., Carter, B., Woodcock, M., Roth, J., Swisher, S., Leighl, N., Digumarthy, S., Mooradian, M., Rotow, J., Wolf, J., Scagliotti, G., Planchard, D., Besse, B., Bivona, T., Gandara, D., Garon, E., Rizvi, N., Camidge, D. R., Schalper, K., Herbst, R., Shaw, A., Neal, J., Wakelee, H., Brahmer, J., Jänne, P., Carbone, D., Aggarwal, C., Pennell, N., Rudin, C., Papadimitrakopoulou, V., & Heymach, J. (2019). MA11.11 STK11/LKB1 genomic alterations are associated with inferior clinical outcomes with chemo-immunotherapy in non-squamous NSCLC. Journal of Thoracic Oncology, 14(10), S294–S295. https://doi.org/10.1016/j.jtho.2019.08.591
doi: 10.1016/j.jtho.2019.08.591
Gadgeel, S. M., Rodriguez-Abreu, D., Felip, E., Esteban, E., Speranza, G., Reck, M., Hui, R., Boyer, M., Garon, E. B., Horinouchi, H., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Piperdi, B., Pietanza, M. C., & Garassino, M. C. (2020). Abstract LB-397: Pembrolizumab plus pemetrexed and platinum vs placebo plus pemetrexed and platinum as first-line therapy for metastatic nonsquamous NSCLC: Analysis of KEYNOTE-189 by STK11 and KEAP1 status. Cancer Research, 80(16 Supplement), LB-397. https://doi.org/10.1158/1538-7445.AM2020-LB-397
doi: 10.1158/1538-7445.AM2020-LB-397
Fujii, T., Naing, A., Rolfo, C., & Hajjar, J. (2018). Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 130, 108–120. https://doi.org/10.1016/j.critrevonc.2018.07.010
doi: 10.1016/j.critrevonc.2018.07.010
pubmed: 30196907